Two Sigma Advisers LP Has $2.11 Million Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Two Sigma Advisers LP grew its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 147.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 242,200 shares of the company's stock after purchasing an additional 144,201 shares during the quarter. Two Sigma Advisers LP owned about 0.31% of Kura Oncology worth $2,110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Rafferty Asset Management LLC increased its holdings in shares of Kura Oncology by 58.7% during the 4th quarter. Rafferty Asset Management LLC now owns 145,614 shares of the company's stock valued at $1,268,000 after acquiring an additional 53,877 shares during the last quarter. ProShare Advisors LLC boosted its position in Kura Oncology by 32.2% during the fourth quarter. ProShare Advisors LLC now owns 24,103 shares of the company's stock worth $210,000 after purchasing an additional 5,873 shares during the period. Prosight Management LP grew its holdings in Kura Oncology by 87.9% during the fourth quarter. Prosight Management LP now owns 1,325,000 shares of the company's stock valued at $11,541,000 after purchasing an additional 619,891 shares during the last quarter. Man Group plc acquired a new position in Kura Oncology during the fourth quarter valued at approximately $163,000. Finally, Millennium Management LLC raised its position in shares of Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the period.

Analyst Ratings Changes

KURA has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. BTIG Research cut shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Mizuho lowered their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, May 19th. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Stock Performance

Shares of KURA stock traded up $0.61 during mid-day trading on Monday, reaching $6.30. The stock had a trading volume of 2,273,948 shares, compared to its average volume of 1,208,469. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48. The firm has a market cap of $545.42 million, a PE ratio of -2.67 and a beta of 0.50. The firm's 50 day simple moving average is $6.09 and its 200 day simple moving average is $7.84. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.